^
Association details:
Biomarker:BRCA2 deletion
Cancer:Prostate Cancer
Drug:Lynparza (olaparib) (PARP inhibitor)
Direction:Sensitive
Evidence:
Evidence Level:
Sensitive: C3 – Early Trials
Source:
Title:

PD04-01: Evaluation of copy number and allelic imbalance of BRCA2 by next-generation sequencing to predict prognosis and drug sensitivity in prostate cancer

Published date:
03/31/2023
Excerpt:
...patients with decreased BRCA2 CN were presumed to have somatic heterozygous or homozygous deletions….In the mCRPC study, 8 of 18 patients with BRCA2 alterations have shown to have BRCA2 deletions. Of the 8 patients, 4 patients with BRCA2 CN less than 0.8 had an OR to the PARP inhibitor olaparib, while the other 4 patients with BRCA2 CN greater than 0.8 did not have an OR to olaparib.
Evidence Level:
Sensitive: C3 – Early Trials
Title:

Biomarkers Associating with PARP Inhibitor Benefit in Prostate Cancer in the TOPARP-B Trial

Published date:
05/27/2021
Excerpt:
BRCA1/2 germline and somatic pathogenic mutations associated with similar benefit from olaparib; greater benefit was observed with homozygous BRCA deletion...Overall, APCs with homozygous BRCA2 deletion are exceptional responders...
DOI:
10.1158/2159-8290.CD-21-0007
Evidence Level:
Sensitive: C3 – Early Trials
New
Title:

DNA-Repair Defects and Olaparib in Metastatic Prostate Cancer

Excerpt:
Of these 16 patients, 14 (88%) had a response to olaparib, including all 7 patients with BRCA2 loss (4 with biallelic somatic loss, and 3 with germline mutations) and 4 of 5 with ATM aberrations.
DOI:
10.1056/NEJMoa1506859
Trial ID: